in

Trials confirm 90% COVID-19 protection of Iranian vaccines

Mohammad Reza Salehi told IRNA that the results of immunogenicity tests on about 35 volunteers show that the vaccine has had a higher immunogenicity protection.

Results show that 90% of those who have received the second dose have shown immunogenicity after two weeks, he added.

He noted that injection of the second dose on 56 volunteers has been carried out.

Earlier, Head of the Executive Office of Imam Khomeini Directives Mohammad Mokhber said the first Iran-made COVID vaccine COV-Iran Barekat – is predicted to be available by late April.

The first injection of the 1st phase of the COVID-19 vaccine human trial produced by Imam Khomeini’s Order Executive Office was done on December 29, 2020.

9376**1416

Follow us on Twitter @IrnaEnglish

Source link